eGlaxoSmithKline As per our previous discussion, there is little doubt anymore but that our HIV / AIDS drugs are well positioned to go to the next level of modern emergent medicine. Whatever treatment modalities that will arise in the future will be Continue Reading...
-- but Glaxo contends that Cipla violates the companies' patents and international intellectual- property agreements"(Boseley, 2002). In moral defense of its actions, Glaxo's CEO, told shareholders "Some people might see patents as the obstacle to g Continue Reading...
He says that if the prices are still too high, the UN should offer subsidies. (Boseley, 2003) 2. Rupert Bondy - Senior Vice President and General Counsel He played a key role in the merger between Glaxo Welcome and SmithKline as well as after the Continue Reading...
Marketing, Product Safety, and Intellectual Property Ethical issues relating to marketing and advertising, intellectual property, and regulation of product safety Various organizations often find themselves in the wrong side of the law when undert Continue Reading...
Patents in the Pharmaceutical Industry Intellectual property theft through piracy and counterfeiting has risen dramatically over the last couple of decades. As a result, the level of activity of pirates and counterfeiters has increased, and so has t Continue Reading...
Japanese-American Biopharmaceutical Industry in the 21st Century Optimizing Ethical Drug Availability Between These Two Pharmaceutical Superpowers" The Japanese-American biopharmaceutical industry represents an ongoing international effort betwee Continue Reading...
